Trinity Biotech(TRIB) - 2025 Q3 - Earnings Call Presentation

Financial Performance - Revenue for Q3 2025 was $14.3 million, compared to $15.2 million in Q3 2024[7] - Like-for-like revenue (excluding discontinued product lines) was $14.2 million in Q3 2025, compared to $14.6 million in Q3 2024[4, 7] - Gross profit increased to $6.5 million in Q3 2025 from $5.3 million in Q3 2024, with gross margin improving to 45.2% from 35.0%[7] - The company achieved positive Adjusted EBITDA of $0.5 million for the quarter, compared to negative $1.4 million in Q3 2024[4] - Net loss was $5.1 million in Q3 2025, compared to $4.8 million in Q3 2024[4] - Basic and diluted loss per ADS was $0.28 in Q3 2025, compared to $0.46 in Q3 2024[4] Key Revenue Drivers - TrinScreen HIV sales were $1.0 million in Q3 2025, compared to $2.4 million in Q3 2024, reflecting the resumption of manufacture[7] - UniGold HIV sales showed strong performance with sales of $2.6 million in Q3 2025, compared to $1.6 million in Q3 2024[7] - Haemoglobin revenue increased to $5.7 million in Q3 2025 from $5.1 million in Q3 2024[7] Expenses and Liquidity - R&D expense was $0.8 million in Q3 2025, compared to $1.0 million in Q3 2024[10] - SG&A expense decreased to $6.2 million in Q3 2025 from $6.5 million in Q3 2024[10] - Cash balance at the end of Q3 2025 was $1.3 million, compared to $2.8 million in Q3 2024[10]